Alexander Leandros Lazarides, MD, discusses research regarding margin assessment in patients with sarcoma.
Alexander Leandros Lazarides, MD
Advertisement
Articles by Alexander Leandros Lazarides, MD
Alexander Leandros Lazarides, MD, resident at Duke University Medical Center, discusses CRM1 as a potential target in osteosarcoma.
Alexander Leandros Lazarides, MD, discusses some of the current challenges in moving the field forward in osteosarcoma.
Advertisement
Latest Updated Articles
Dr. Lazarides on Challenges in Moving the Field of Osteosarcoma ForwardPublished: January 4th 2020 | Updated:
Dr. Lazarides on CRM1 as a Potential Target in OsteosarcomaPublished: February 22nd 2020 | Updated:
Dr. Lazarides on Research Regarding Margin Assessment in SarcomaPublished: February 28th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5